Cooperative Agreement 2151582

Award Date 3/1/22
Completion Date 12/31/25
Dollars Obligated $996K
Federal Grant Program
47.084
Assistance Type
Cooperative Agreement
Place of Performance
Swissvale, PA 15218, USA
Similar Awards
This $999,998 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports the development of Renerva LLC's Peripheral Nerve Matrix (PNM) technology. PNM is a tissue-based hydrogel derived from porcine nerve that aims to improve functional outcomes for patients with challenging peripheral nerve gap injuries. The Phase I project will optimize the PNM...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $296,151 to Insoma Bio, Inc. to investigate the use of their proprietary Fractomer biomaterial to improve outcomes after peripheral nerve repair. The project aims to demonstrate that Fractomer, an injectable polypeptide scaffold, can provide the necessary mechanical support and...
This Project Grant awarded by the National Science Foundation (CFDA 47.041 - Engineering) to Cleveland State University (CSU) provides $500,000 in funding from January 1, 2025 to December 31, 2027 to develop bioprinted tissue scaffolds with Schwann cell density gradients and electrical conductivity for peripheral nerve regeneration. The goal is to understand how Schwann cell density gradients and electrical properties within the scaffolds can enhance the regeneration of injured peripheral...
This National Science Foundation (NSF) Cooperative Agreement under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $1,016,000 in funding to Nostopharma LLC to develop an innovative, sustained-release, and biodegradable drug delivery platform for localized treatment of post-traumatic injuries. The goal is to create a medication delivery system using anti-inflammatory nanoparticles embedded with a Hedgehog pathway antagonist, arsenic trioxide, to address unmet...
This Small Business Innovation Research (SBIR) Phase I project, awarded by the National Science Foundation (NSF) under the TIP (Technology, Innovation, and Partnerships) program (CFDA 47.084), aims to develop a novel, multifunctional neural probe for advancing neuroscience research. The $254,456 grant awarded to Neurobionics Inc. on August 15, 2024, will fund the integration of electrical, optical, and chemical capabilities into a single implantable device. This versatile tool will enable...
This $252,906 National Science Foundation project grant supports the development of scalable manufacturing methods for peptide amphiphile molecules by Amphix Bio Inc. The goal is to advance a safer and more affordable alternative to recombinant proteins currently used in spinal fusion surgeries. Over 500,000 such surgeries are performed annually in the U.S. to treat back and neck pain. While peptide amphiphiles show promise for reducing biological dose needs and offering consistent outcomes,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,976 to Ecate LLC aims to develop a novel intraspinal stimulator system to restore sensation and volitional motor control in spinal cord injury patients. The project will fabricate nanopatterned stimulating electrodes coupled with custom CMOS chips to deliver spatially selective electrical stimulation to the spinal cord. This closed-loop neural interface system is intended...
This Project Grant award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program provides $274,841 to XN Health Inc. to develop a novel transtracheal phrenic nerve stimulation device. The device aims to reduce injury rates caused by mechanical ventilation by stimulating the phrenic nerves to induce diaphragmatic contractions, thereby increasing lung inflation and supporting protective ventilation for critically ill patients. The...
Nostopharma LLC was awarded a $256,000 Small Business Technology Transfer Phase I Project Grant from the National Science Foundation to develop a sustained-release, biodegradable nanoparticle drug delivery system for treatment of soft tissue trauma complications. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the 12-month project beginning March 1, 2022 aims to demonstrate in vitro and in vivo feasibility of modulating the ectopic bone microenvironment...
This Project Grant award of $295,000.00 from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel implantable system leveraging distraction osteogenesis as a treatment for diabetic foot ulcers (DFUs). The project aims to design and develop a low-profile implantable transverse tibial transport device with an active mechanical mechanism to transversely distract or retract a cut tibia bone segment in a...

SBIR PHASE II: A NOVEL PERIPHERAL NERVE MATRIX PLATFORM FOR SEVERE ACUTE PERIPHERAL NERVE INJURIES -THE BROADER IMPACT /COMMERCIAL POTENTIAL OF THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT WILL ENHANCE CLINICAL OUTCOMES FOR PATIENTS WITH A TRAUMATIC OR PALLIATIVE PERIPHERAL NERVE INJURY (PNI). IN THE U.S., 20 MILLION PEOPLE SUFFER FROM PNIS, WITH A HIGH PREVALENCE AMONG YOUNG INDIVIDUALS AND A TOTAL ECONOMIC COST TO SOCIETY IN EXCESS OF $150 BILLION PER YEAR. ACUTE PNIS ACCOUNT FOR MORE THAN 500,000 ANNUAL SURGICAL PROCEDURES IN THE U.S AND FREQUENTLY RESULT IN PERMANENT DISABILITY. THIS PROJECT DEVELOPS A PLATFORM TECHNOLOGY WITH THE POTENTIAL TO ADDRESS MANY TYPES OF PNI. THIS SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE I PROJECT WILL CREATE A NOVEL NERVE GRAFT/CONDUIT FOR NERVE GAP INJURY REPAIR AND A NERVE CAP. THE PROJECT GOAL IS TO ADVANCE A SOLUTION TO IMPROVE THE NERVE FUNCTIONAL OUTCOME WHILE STILL REDUCING THE TENSION ACROSS THE REPAIR. IT PROVIDES A TISSUE-LIKE MATRIX THAT ALLOWS ALIGNED NERVE GROWTH OUT OF THE FREE NERVE ENDING. THE TECHNOLOGY IS DERIVED FROM DECELLULARIZED PORCINE NERVE TISSUE AND MAINTAINS NATIVE STRUCTURAL AND FUNCTIONAL PROTEINS, PROVIDING AN IDEAL ENVIRONMENT FOR NERVE REPAIR AND REGENERATION. THIS PROJECT CONDUCTS IN-VIVO STUDIES, STERILIZATION DEMONSTRATIONS, AND LYOPHILIZATION. SUPPLY CHAIN SECURITY, PACKAGING DEVELOPMENT, AND TOOLING WILL BE DEVELOPED IN PREPARATION FOR COMMERCIAL LAUNCH. THIS AWARD REFLECTS NSF'S STATUTORY MISSION AND HAS BEEN DEEMED WORTHY OF SUPPORT THROUGH EVALUATION USING THE FOUNDATION'S INTELLECTUAL MERIT AND BROADER IMPACTS REVIEW CRITERIA.

Posted 2/24/22, 12:00 AM